Rosen Law Firm Investigates ADMA Biologics for Misleading Information
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 01 2026
0mins
Source: PRnewswire
- Securities Claims Investigation: Rosen Law Firm has launched an investigation into ADMA Biologics due to allegations of issuing materially misleading business information, which could severely impact the company's reputation and stock price if proven true.
- Stock Price Plunge: On March 24, 2026, ADMA Biologics' shares fell by 16.6% after short seller Culper Research alleged that the company engaged in channel stuffing to inflate revenue, indicating a significant loss of market confidence in the company's financial transparency.
- Class Action Preparation: The Rosen Law Firm is preparing a class action to recover investor losses, with no upfront costs for participants, thereby reducing legal risks for investors and encouraging more affected parties to join the lawsuit.
- Firm's Track Record: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, showcasing its expertise and resource advantages in handling similar cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ADMA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ADMA
About ADMA
ADMA Biologics, Inc. is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The Company manufactures and markets three United States Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immune deficiencies and the prevention of certain infectious diseases: ASCENIV (immune globulin intravenous, human-slra 10% liquid) for the treatment of primary humoral immunodeficiency (PI); BIVIGAM (immune globulin intravenous, human) for the treatment of PI; and NABI-HB (hepatitis B immune globulin, human) to provide enhanced immunity against the hepatitis B virus. Through its ADMA BioCenters subsidiary, the Company also operates as an FDA-approved source plasma collector in the United States, which provides its blood plasma for the manufacture of its products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ADMA Biologics Faces Class Action Lawsuit
- Lawsuit Background: Gainey McKenna & Egleston has filed a securities class action lawsuit in the U.S. District Court for New Jersey on behalf of all ADMA Biologics investors who purchased shares between August 9, 2024, and March 25, 2026, alleging undisclosed related party transactions and inadequate internal controls.
- Allegation Details: The complaint claims that ADMA engaged in channel stuffing to inflate revenue figures and failed to disclose related party transactions, resulting in materially misleading statements about the company's business and prospects, which could mislead investors.
- Stock Price Reaction: Following a report from Culper Research on March 24, 2026, ADMA's stock price fell by $2.26, or 16.6%, and dropped another $1.70 the next day, indicating increasing market concerns regarding the company's financial health and operational integrity.
- Investor Action: Affected investors are urged to contact the law firm before the August 10, 2026, lead plaintiff motion deadline to ensure their rights are represented in the class action lawsuit.
See More
Shareholder Class Action Filed Against ADMA Biologics
- Lawsuit Allegations: ADMA Biologics, Inc. faces a shareholder class action lawsuit alleging false and misleading statements regarding its business, including undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls.
- Investor Losses: Investors who purchased ADMA shares between August 9, 2024, and March 25, 2026, and suffered losses are encouraged to contact legal counsel, highlighting significant investor concerns over the company's transparency and compliance.
- Legal Representation: Holzer & Holzer, LLC, a top-rated securities litigation law firm, has recovered hundreds of millions for shareholders since its inception in 2000, demonstrating its expertise in protecting investor rights against corporate misconduct.
- Litigation Deadline: Investors must apply to be appointed lead plaintiff by August 10, 2026, underscoring the importance of timely legal action to safeguard their interests.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiation: The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false and misleading statements during this period, resulting in investor losses.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file a motion with the court by August 10, 2026, to establish their representative status in the class action, ensuring their rights are protected throughout the litigation process.
- Compensation Mechanism: Investors participating in the class action may be entitled to compensation without any upfront costs through a contingency fee arrangement, which reduces the financial burden on investors and encourages more victims to join the lawsuit.
- Law Firm Background: The Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
ADMA Biologics Faces Securities Fraud Lawsuit
- Lawsuit Background: Block & Leviton has announced a securities fraud lawsuit against ADMA Biologics and certain executives, alleging misleading investors from 2024 to 2026, resulting in significant investor losses; the lawsuit claims ADMA falsely reported revenue growth through a channel-stuffing scheme while failing to disclose a related-party distribution relationship with Genesis BioPharma Services.
- Stock Price Volatility: Following the March 24, 2026 report by Culper Research, which revealed that ADMA's growth was driven by excess inventory rather than genuine demand, the company's stock price plummeted from approximately $13.59 to $8.29, indicating market concerns regarding the company's financial health and transparency.
- Investor Eligibility: Investors who purchased ADMA stock between August 9, 2024, and March 25, 2026, and have incurred losses are encouraged to contact Block & Leviton to explore recovery options, suggesting that the lawsuit could impact a broad base of investors who may be eligible for compensation.
- Whistleblower Program: Whistleblowers with non-public information about ADMA are encouraged to assist in the investigation, as they may receive rewards of up to 30% of any successful recovery by providing original information to the SEC, highlighting the potential for increased legal scrutiny and compliance risks for the company.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, particularly concerning the authenticity of its reported 20% revenue growth in 2025.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced distributors to stockpile ASCENIV to inflate revenue figures, suggesting that without this scheme, the company would have faced a 3% revenue decline instead of the reported 20% growth.
- Stock Price Impact: This news caused ADMA Biologics' stock price to plummet by 29% over two trading days, dropping from $13.59 per share on March 23 to $9.63 per share on March 25, indicating significant market concerns regarding the company's financial health.
- Legal Options: Investors are encouraged to contact BFA for legal support, with the firm offering representation on a contingency fee basis, highlighting its commitment to protecting investor rights.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, encouraging investors to seek further information regarding their legal options.
- Revenue Growth Scrutiny: ADMA reported a 20% revenue growth in 2025, but allegations suggest this was achieved through a channel stuffing scheme to obscure declining demand, with actual revenues potentially declining by 3% had the scheme not been employed.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed ADMA's channel stuffing practices, the company's stock price fell by 29% over two trading days, from $13.59 on March 23 to $9.63 on March 25, indicating significant market concerns over its financial transparency.
- Legal Implications: Investors may have legal recourse, with BFA offering representation on a contingency basis, highlighting a commitment to protecting investor rights while potentially impacting ADMA's future financing capabilities.
See More
ADMA Biologics Faces Class Action Lawsuit
- Lawsuit Background: Gainey McKenna & Egleston has filed a securities class action lawsuit in the U.S. District Court for New Jersey on behalf of all ADMA Biologics investors who purchased shares between August 9, 2024, and March 25, 2026, alleging undisclosed related party transactions and inadequate internal controls.
- Allegation Details: The complaint claims that ADMA engaged in channel stuffing to inflate revenue figures and failed to disclose related party transactions, resulting in materially misleading statements about the company's business and prospects, which could mislead investors.
- Stock Price Reaction: Following a report from Culper Research on March 24, 2026, ADMA's stock price fell by $2.26, or 16.6%, and dropped another $1.70 the next day, indicating increasing market concerns regarding the company's financial health and operational integrity.
- Investor Action: Affected investors are urged to contact the law firm before the August 10, 2026, lead plaintiff motion deadline to ensure their rights are represented in the class action lawsuit.
See More
Shareholder Class Action Filed Against ADMA Biologics
- Lawsuit Allegations: ADMA Biologics, Inc. faces a shareholder class action lawsuit alleging false and misleading statements regarding its business, including undisclosed related party transactions, channel stuffing to inflate revenue, and inadequate internal controls.
- Investor Losses: Investors who purchased ADMA shares between August 9, 2024, and March 25, 2026, and suffered losses are encouraged to contact legal counsel, highlighting significant investor concerns over the company's transparency and compliance.
- Legal Representation: Holzer & Holzer, LLC, a top-rated securities litigation law firm, has recovered hundreds of millions for shareholders since its inception in 2000, demonstrating its expertise in protecting investor rights against corporate misconduct.
- Litigation Deadline: Investors must apply to be appointed lead plaintiff by August 10, 2026, underscoring the importance of timely legal action to safeguard their interests.
See More
Class Action Lawsuit Filed Against ADMA Biologics
- Class Action Initiation: The Rosen Law Firm has filed a class action lawsuit on behalf of investors who purchased ADMA Biologics securities between August 9, 2024, and March 25, 2026, alleging that the company made materially false and misleading statements during this period, resulting in investor losses.
- Legal Procedure Requirements: Investors wishing to serve as lead plaintiffs must file a motion with the court by August 10, 2026, to establish their representative status in the class action, ensuring their rights are protected throughout the litigation process.
- Compensation Mechanism: Investors participating in the class action may be entitled to compensation without any upfront costs through a contingency fee arrangement, which reduces the financial burden on investors and encourages more victims to join the lawsuit.
- Law Firm Background: The Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and influence in handling similar cases.
See More
ADMA Biologics Faces Securities Fraud Lawsuit
- Lawsuit Background: Block & Leviton has announced a securities fraud lawsuit against ADMA Biologics and certain executives, alleging misleading investors from 2024 to 2026, resulting in significant investor losses; the lawsuit claims ADMA falsely reported revenue growth through a channel-stuffing scheme while failing to disclose a related-party distribution relationship with Genesis BioPharma Services.
- Stock Price Volatility: Following the March 24, 2026 report by Culper Research, which revealed that ADMA's growth was driven by excess inventory rather than genuine demand, the company's stock price plummeted from approximately $13.59 to $8.29, indicating market concerns regarding the company's financial health and transparency.
- Investor Eligibility: Investors who purchased ADMA stock between August 9, 2024, and March 25, 2026, and have incurred losses are encouraged to contact Block & Leviton to explore recovery options, suggesting that the lawsuit could impact a broad base of investors who may be eligible for compensation.
- Whistleblower Program: Whistleblowers with non-public information about ADMA are encouraged to assist in the investigation, as they may receive rewards of up to 30% of any successful recovery by providing original information to the SEC, highlighting the potential for increased legal scrutiny and compliance risks for the company.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Background: Bleichmar Fonti & Auld LLP has announced an investigation into ADMA Biologics for potential violations of federal securities laws, particularly concerning the authenticity of its reported 20% revenue growth in 2025.
- Channel Stuffing Allegations: A report by Culper Research claims that ADMA induced distributors to stockpile ASCENIV to inflate revenue figures, suggesting that without this scheme, the company would have faced a 3% revenue decline instead of the reported 20% growth.
- Stock Price Impact: This news caused ADMA Biologics' stock price to plummet by 29% over two trading days, dropping from $13.59 per share on March 23 to $9.63 per share on March 25, indicating significant market concerns regarding the company's financial health.
- Legal Options: Investors are encouraged to contact BFA for legal support, with the firm offering representation on a contingency fee basis, highlighting its commitment to protecting investor rights.
See More
ADMA Biologics Under Investigation for Securities Violations
- Investigation Announcement: Bleichmar Fonti & Auld LLP has initiated an investigation into ADMA Biologics for potential violations of federal securities laws, encouraging investors to seek further information regarding their legal options.
- Revenue Growth Scrutiny: ADMA reported a 20% revenue growth in 2025, but allegations suggest this was achieved through a channel stuffing scheme to obscure declining demand, with actual revenues potentially declining by 3% had the scheme not been employed.
- Stock Price Plunge: Following the release of a report by Culper Research that exposed ADMA's channel stuffing practices, the company's stock price fell by 29% over two trading days, from $13.59 on March 23 to $9.63 on March 25, indicating significant market concerns over its financial transparency.
- Legal Implications: Investors may have legal recourse, with BFA offering representation on a contingency basis, highlighting a commitment to protecting investor rights while potentially impacting ADMA's future financing capabilities.
See More
